These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10560801)

  • 1. Individualized drug dosage in patients treated with continuous hemofiltration.
    Keller F; Böhler J; Czock D; Zellner D; Mertz AK
    Kidney Int Suppl; 1999 Nov; (72):S29-31. PubMed ID: 10560801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage.
    Böhler J; Donauer J; Keller F
    Kidney Int Suppl; 1999 Nov; (72):S24-8. PubMed ID: 10560800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration.
    Arzuaga A; Maynar J; Gascón AR; Isla A; Corral E; Fonseca F; Sánchez-Izquierdo JA; Rello J; Canut A; Pedraz JL
    J Clin Pharmacol; 2005 Feb; 45(2):168-76. PubMed ID: 15647409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
    Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
    Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
    Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration.
    McLaughlin MM; Masic I; Gerzenshtein L
    Int J Clin Pharm; 2017 Feb; 39(1):37-40. PubMed ID: 27888453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
    Banyai M; Thalhammer F; El-Menyawi I; Heinz G; Traunmüller F; Siostrzonek P
    Clin Pharmacol Ther; 2000 Apr; 67(4):368-72. PubMed ID: 10801245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration.
    Joos B; Schmidli M; Keusch G
    Nephrol Dial Transplant; 1996 Aug; 11(8):1582-5. PubMed ID: 8856215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin.
    Meyer B; Ahmed el Gendy S; Delle Karth G; Locker GJ; Heinz G; Jaeger W; Thalhammer F
    Kidney Blood Press Res; 2003; 26(2):135-40. PubMed ID: 12771540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Catecholamines During Hemofiltration in Pediatric Patients.
    Freter AE; Husayni TS; Reyes G
    J Cardiovasc Pharmacol Ther; 1998 Jul; 3(3):235-238. PubMed ID: 10684503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics during continuous renal replacement therapy.
    Keller E
    Int J Artif Organs; 1996 Feb; 19(2):113-7. PubMed ID: 8647606
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
    Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
    J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of anti-infective agents in continuous hemofiltration].
    Jaumain H; Clapson D; Allavéna MC; Allaouchiche B
    Presse Med; 1998 Oct; 27(30):1536-44. PubMed ID: 9810313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes.
    Frank RD; Farber H; Stefanidis I; Lanzmich R; Kierdorf HP
    Kidney Int Suppl; 1999 Nov; (72):S41-5. PubMed ID: 10560804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of vancomycin in continuous veno-venous hemofiltration].
    Gu Q; Zhu ZH; Ge M; Ge WH
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Feb; 15(2):114-6. PubMed ID: 12857476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction.
    New AM; Nei SD; Kashani KB; Rabinstein AA; Frazee EN
    Neurocrit Care; 2016 Aug; 25(1):141-4. PubMed ID: 26800696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenytoin removal by continuous venovenous hemofiltration.
    Oltrogge KM; Peppard WJ; Saleh M; Regner KR; Herrmann DJ
    Ann Pharmacother; 2013 Sep; 47(9):1218-22. PubMed ID: 24259740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects and applications of hemofiltration.
    Weiss LG
    Scand J Urol Nephrol Suppl; 1989; 118():1-64. PubMed ID: 2785286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.